INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS
Starting soon · Not applicable
Conditions studied: Drug Resistance, Microbial, Biomarkers, Urinary Tract Infections (UTI's), Antibacterial Agents
In brief
Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\<2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.
Key facts
- Study ID
- NCT07675018
- Run by
- University Hospital, Limoges
- People needed
- 204
- Starts
- 2026-09-15
- Expected to finish
- 2028-09-21
- Last updated by the study team
- 2026-07-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years old; Hospitalized or admitted to the Emergency department;
- Diagnosis of non-severe (qSOFA < 2) urinary tract infection coupled with fever ≥ 38°C or < 36°C
- Presence of bacteria in the fresh urine sample and/or GNB on the Gram stain
- Empirical parenteral antibiotic therapy required; Hospitalization required;
- Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months
- Informed consent of the patient or their representative
You may not qualify if…
- Pregnant and/or breastfeeding
- Neutropenia (absolute neutrophil count < 500 / mm3)
- Severe UTI with sepsis (qSOFA ≥ 2) or septic shock
- Urinary derivation required (ureteral catheter/per-cutaneous nephrostomy) except for simple urinary catheterization
- Known allergy to β-lactams
- Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months
- Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem
- Not affiliated to Social Security
Where it is running
- CHRU Tours, Hôpital Trousseau — Chambray-lès-Tours, France
- Grenoble university hospital — La Tronche, France
- Limoges university hospital — Limoges, France
- Hopital lariboisière — Paris, France
- Hôpital Saint Louis - APHP — Paris, France
- Groupe Hospitalier Universitaire Bichat-Claude Bernard - APHP — Paris, France
- CHU de Reims — Reims, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.